Savant Capital LLC Invests $226,000 in REGENXBIO Inc. $RGNX

Savant Capital LLC purchased a new position in REGENXBIO Inc. (NASDAQ:RGNX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 27,481 shares of the biotechnology company’s stock, valued at approximately $226,000. Savant Capital LLC owned about 0.05% of REGENXBIO at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Brooklyn Investment Group lifted its stake in REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 3,466 shares during the last quarter. Entropy Technologies LP acquired a new stake in shares of REGENXBIO in the 1st quarter worth about $107,000. Pallas Capital Advisors LLC lifted its position in REGENXBIO by 67.1% in the 2nd quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 6,992 shares during the last quarter. Caliber Wealth Management LLC KS bought a new stake in REGENXBIO in the 1st quarter valued at about $126,000. Finally, Corton Capital Inc. boosted its stake in REGENXBIO by 54.6% during the 1st quarter. Corton Capital Inc. now owns 20,528 shares of the biotechnology company’s stock valued at $147,000 after purchasing an additional 7,252 shares during the period. 88.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on RGNX shares. Wall Street Zen cut REGENXBIO from a “hold” rating to a “sell” rating in a report on Sunday. Barclays lowered their target price on REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research report on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a report on Monday, September 8th. Finally, Royal Bank Of Canada upped their price objective on shares of REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.63.

REGENXBIO Price Performance

RGNX opened at $10.93 on Thursday. REGENXBIO Inc. has a 1-year low of $5.03 and a 1-year high of $13.93. The company has a market capitalization of $553.28 million, a price-to-earnings ratio of -3.15 and a beta of 1.23. The business has a 50 day moving average price of $11.07 and a two-hundred day moving average price of $9.61.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.18. The company had revenue of $29.73 million for the quarter, compared to the consensus estimate of $24.41 million. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%. Equities analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Insider Buying and Selling

In other REGENXBIO news, CEO Curran Simpson sold 20,811 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $12.62, for a total value of $262,634.82. Following the completion of the sale, the chief executive officer directly owned 216,162 shares of the company’s stock, valued at approximately $2,727,964.44. This represents a 8.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 36,169 shares of company stock valued at $416,598 in the last quarter. 12.79% of the stock is currently owned by insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.